Companies / BioXcel Therapeutics, Inc. / Activity
Activity — BioXcel Therapeutics, Inc.
22 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2023 as of | Barclays PLC 13F manager | Add | Common stock | $949.6K | +51K +990.79% | 56,023 0.18% of shares | low |
| Q2 2023 as of | Barclays PLC 13F manager | Add | Common stock | $297.7K | +45K +79.78% | 100,720 0.33% of shares | low |
| Q3 2023 as of | Barclays PLC 13F manager | Trim | Common stock | $-235.5K | -93K -92.40% | 7,656 0.02% of shares | low |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common Stock | $136.1K | +102K +5.53% | 1,936,760 6.27% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $134.0K | +95K +112.61% | 179,433 0.58% of shares | low |
| Q1 2026 as of | &Partners 13F manager | New | Common Stock | $108.4K | +81K | 80,864 0.26% of shares | low |
| Q4 2023 as of | Barclays PLC 13F manager | Add | Common stock | $59.7K | +20K +264.35% | 27,895 0.09% of shares | low |
| Q2 2026 as of | Quadrature Capital Ltd 13F manager | New | Common Stock | $53.6K | +38K | 38,038 0.12% of shares | low |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $40.7K | +29K +45.71% | 92,118 0.30% of shares | low |
| Q1 2024 as of | Barclays PLC 13F manager | Trim | Common stock | $-37.0K | -13K -47.04% | 14,772 0.05% of shares | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | Common Stock | $32.2K | +24K +11.64% | 230,168 0.75% of shares | low |
| Q2 2024 as of | Barclays PLC 13F manager | Trim | Common stock | $-18.8K | -15K -99.07% | 137 <0.01% of shares | low |
| Q4 2025 as of | Bank of America Corp /De 13F manager | Trim | Common Stock | $-8.7K | -5K -78.99% | 1,446 <0.01% of shares | low |
| Q1 2025 as of | Barclays PLC 13F manager | New | Common Stock | $3.9K | +2K | 1,910 <0.01% of shares | low |
| Q2 2025 as of | Barclays PLC 13F manager | Trim | Common Stock | $-3.3K | -2K -99.58% | 8 <0.01% of shares | low |
| Q1 2026 as of | Gsa Capital Partners LLP 13F manager | Exit | Common Stock | $-192 | -120K -100.00% | 0 | low |
| Q1 2026 as of | BNP Paribas Financial Markets 13F manager | Add | Common Stock | $63 | +47 +391.67% | 59 <0.01% of shares | low |
| Q1 2025 as of | Barclays PLC 13F manager | Exit | Common stock | $-33 | -88 -100.00% | 0 | low |
| Q3 2024 as of | Barclays PLC 13F manager | Trim | Common stock | $-30 | -49 -35.77% | 88 <0.01% of shares | low |
| Q3 2025 as of | Barclays PLC 13F manager | Exit | Common Stock | $-14 | -8 -100.00% | 0 | low |
| Q4 2025 as of | Elevation Point Wealth Partners, LLC 13F manager | Exit | Common Stock | $-2 | -1 -100.00% | 0 | low |
| Q2 2025 as of | Elevation Point Wealth Partners, LLC 13F manager | New | Common Stock | $2 | +1 | 1 <0.01% of shares | low |